Skip to main content

Peer Review reports

From: Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

Original Submission
28 Oct 2021 Submitted Original manuscript
25 Nov 2021 Reviewed Reviewer Report
9 Jan 2022 Reviewed Reviewer Report
2 Feb 2022 Author responded Author comments - John M. Mariadason
9 Feb 2022 Author responded Author comments - John M. Mariadason
Resubmission - Version 2
2 Feb 2022 Submitted Manuscript version 2
23 Feb 2022 Reviewed Reviewer Report
15 Mar 2022 Reviewed Reviewer Report
25 Mar 2022 Author responded Author comments - John M. Mariadason
Resubmission - Version 3
25 Mar 2022 Submitted Manuscript version 3
31 Mar 2022 Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
1 Apr 2022 Editorially accepted
2 May 2022 Article published 10.1186/s12885-022-09478-4

You can find further information about peer review here.

Back to article page